Identification of protective components of two major outer membrane proteins of spotted fever group rickettsiae

American Journal of Tropical Medicine and Hygiene

Volumn 65, Issue 4, 2001, Pages 371-378

  Diaz Montero C M ^a   Feng, H M ^a   Crocquet Valdes, P A ^a   Walker, D H ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA FRAGMENT; DNA VACCINE; GENE PRODUCT; OUTER MEMBRANE PROTEIN; PLASMID DNA; PROTEIN ROMPA; PROTEIN ROMPB; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOUTONNEUSE FEVER; CELL PROLIFERATION; CELL PROTECTION; CELL SPECIFICITY; CONTROLLED STUDY; GENETIC RECOMBINATION; IMMUNIZATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE VIRULENCE; PROTEIN DETERMINATION; RICKETTSIA CONORII; RICKETTSIOSIS; ROCKY MOUNTAIN SPOTTED FEVER; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0034765244     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.65.371     Document Type: Article

References (49)

1. Studies on Rocky Mountain spotted fever
2. Pathogenesis of circulatory failure in Rocky Mountain spotted fever. Alteration in the blood volume and the thiocyanate space at various stages of the disease
3. Spotted fever group rickettsioses
4. Immune responses to Rickettsia akari infection in congenitally athymic nude mice
5. Role of T lymphocytes in Rickettsia conorii infection
6. Infection of genetically immunodeficient mice with Rickettsia conorii
7. Effect of immunosuppression on Rickettsia rickettsii infection in guinea pigs
8. Role of T-lymphocyte subsets in immunity to spotted fever group rickettsiae
9. Depletion of gamma interferon and tumor necrosis factor alpha in mice with Rickettsia conorii-infected endothelium: Impairment of rickettsicidal nitric oxide production resulting in fatal, overwhelming rickettsial disease
10. Cytokine-induced, nitric oxide-dependent, intra-cellular antirickettsial activity of mouse endothelial cells
11. National surveillance for Rocky Mountain spotted fever, 1981-1992: Epidemiologic summary and evaluation of risk factors for fatal outcome
12. Mediterranean spotted fever: Clinical, laboratory and epidemiological features of 199 cases
13. Tick-borne diseases in Texas: A 10-year retrospective examination of cases
14. Rocky Mountain spotted fever: Vaccination of monkeys and man
15. Use of yolk sac of developing chick embryo as medium for growing rickettsiae of Rocky Mountain spotted fever and typhus groups
16. Serodiagnosis of Rocky Mountain spotted fever: Comparison of IgM and IgG enzyme-linked immuno-sorbent assays and indirect fluorescent antibody test
17. Rocky Mountain spotted fever: Results of fifteen years' prophylactic vaccination
18. Rocky Mountain spotted fever: A comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii
19. A protective protein antigen of Rickettsia rickettsi has tandemly repeated, near-identical sequences
20. Comparative antigenic analysis of spotted fever group rickettsiae from Israel and other closely related organisms
21. rOmpA is a critical protein for the adhesion of Rickettsia rickettsii to host cells
22. Role of major surface antigens of Rickettsia japonica in the attachment to host cells
23. Antigenic diversity of Rickettsia conorii
24. Evidence for proteolytic cleavage of the 120-kilodalton outer membrane protein of rickettsiae: Identification of an avirulent mutant deficient in processing
25. Characterization of monoclonal antibodies protecting mice against Rickettsia rickettsii
26. Antigenic heterogeneity in high- and low-virulence strains of Rickettsia rickettsii revealed by monoclonal antibodies
27. The great escape: Structure and function of the autotransporter proteins
28. Structural analyses of the 120-kDa serotype protein antigens of typhus group rickettsiae: Comparison with other S-layer proteins
29. Analysis of T-cell-dependent and -independent antigens of Rickettsia conorii with monoclonal antibodies
30. Reactivity of monoclonal antibodies to Rickettsia rickettsii with spotted fever and typhus group rickettsiae
31. Neutralizing activity of monoclonal antibodies to heat-sensitive and heat-resistant epitopes of Rickettsia rickettsii surface proteins
32. Protection of guinea-pigs from experimental Rocky Mountain spotted fever by immunization with baculovirus-expressed Rickettsia rickettsii rOmpA protein
33. A recombinant Rickettsia conorii vaccine protects guinea pigs from experimental boutonneuse fever and Rocky Mountain spotted fever
34. The surface protein antigen of Rickettsia typhi: In vitro and in vivo immunogenicity and protective efficacy in mice
35. The species-specific surface protein antigen of Rickettsia typhi: Immunogenicity and protective efficacy in guinea pigs
36. Some characteristics of heavy and light bands of Rickettsia prowazekii on renografin gradients
37. The 120 kilodalton outer membrane protein (rOmp B) of Rickettsia rickettsii is encoded by an unusually long open reading frame: Evidence for protein processing from a large precursor
38. Serologic typing of rickettsiae of the spotted fever group by microimmunofluorescence
39. Heterologous protection against influenza by injection of DNA encoding a viral protein
40. Nucleic acid immunization: Concepts and techniques associated with third generation vaccines
41. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors
42. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
43. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
44. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
45. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
46. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
47. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
48. Can soluble antigens induce CD8+ cytotoxic T-cell responses? A paradox revisited
49. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen